A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes A multicentre double-blind placebo-controlled study in Australia and internationally.
This study investigates whether treatment with fenofibrate reduces the risk of people with type 1 diabetes (T1D) suffering from progression of diabetic eye disease. Fenofibrate is a drug that lowers fats in the blood. Other important purposes of the study are to determine whether treatment with fenofibrate reduces the risk of people with T1D developing blood vessel (vascular) complications such as kidney disease, nerve disease, heart attack and other cardiovascular disease (CVD), and to identify whether retinal (back of the eye) photographic changes and specific blood and urine results can predict important medical conditions. Fenofibrate has been used in European countries for over 30 years and in Australia for over 10 years. It is approved in Australia to treat abnormal blood fats and also to reduce diabetic retinopathy progression in adults with type 2 diabetes (T2D). However, it is not known whether people with T1D would also benefit from this treatment.